3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Breast Neoplasms
6
Fallopian Tube Neoplasms
3
Endometrial Neoplasms
3
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Esophageal Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Recurrence
1
Neoplasms
1
Carcinosarcoma
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Brenner Tumor
1
Anus Neoplasms
1
Interventions
tisagenlecleucel
2
fludarabine
2
blinatumomab
2
Cyclophosphamide
2
zanubrutinib
1
selinexor
1
revumenib
1
niraparib
1
nilotinib
1
ivosidenib
1
imetelstat
1
ibrutinib
1
entrectinib
1
dostarlimab
1
brexucabtagene autoleucel
1
avapritinib
1
asciminib
1
Standard of Care
1
Paclitaxel
1
Imatinib Mesylate
1
GRN163L peptide
1
Drug Therapy
1
Dexamethasone
1
Dasatinib
1
Carboplatin
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Recurrence
×
Paclitaxel
×
Clear all
NCT03981796
2025-09-03
RUBY
Tesaro, Inc.
Phase 3
Active not recruiting
785 enrolled
2 FDA